【佳學基因檢測】實體瘤個體化醫(yī)療的新策略：分子標志物和臨床試驗設計

腫瘤基因檢測需要多長時間香港

根據(jù)如何選擇有效的靶向藥物治療認識到《Clin Cancer Res》在.?2014 Sep 1;20(17):4425-35.發(fā)表了一篇題目為《實體瘤個體化醫(yī)療的新策略：分子標志物和臨床試驗設計》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Juliane M Jürgensmeier?,?Joseph P Eder?,?Roy S Herbst?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤標志物研究內(nèi)容關鍵詞：

實體瘤,個體化醫(yī)療,新策略,伴隨檢測,基因檢測

腫瘤靶向治療基因檢測臨床應用結(jié)果

了解腫瘤生物學的信號通路的描述，加上允許廣泛分子譜分析和數(shù)據(jù)分析的技術(shù)的快速發(fā)展，導致了腫瘤學個性化醫(yī)療的新時代?，F(xiàn)在，許多學術(shù)機構(gòu)在提出治療建議之前，定期在個性化醫(yī)學腫瘤委員會會議上對患者進行分析并討論他們的病例。制藥公司發(fā)起的臨床試驗通常需要特定的基因檢測標志物才能注冊，或者至少為未來的標志物探索多種選擇。除了少數(shù)被批準用于治療組織學和分子明確的腫瘤患者的靶向藥物外，大量正在開發(fā)的新型靶向藥物正在進行臨床研究，并通過基因檢測進行伴隨分析以確定反應賊佳的患者群體。盡管目前分析的重點在于遺傳分析，但正在開發(fā)額外的 RNA、蛋白質(zhì)和免疫參數(shù)測試并將其納入臨床研究，這些方法可能會對未來的患者選擇和治療方法做出重大貢獻。隨著腫瘤生物學和人類遺傳學的進步已經(jīng)確定了有希望的腫瘤靶點，正在進行的新藥臨床評估現(xiàn)在需要證明這一承諾是否可以轉(zhuǎn)化為對患者的益處。

腫瘤發(fā)生與反復轉(zhuǎn)移國際數(shù)據(jù)庫描述：

The delineation of signaling pathways to understand tumor biology combined with the rapid development of technologies that allow broad molecular profiling and data analysis has led to a new era of personalized medicine in oncology. Many academic institutions now routinely profile patients and discuss their cases in meetings of personalized medicine tumor boards before making treatment recommendations. Clinical trials initiated by pharmaceutical companies often require specific markers for enrollment or at least explore multiple options for future markers. In addition to the still small number of targeted agents that are approved for the therapy of patients with histological and molecularly defined tumors, a broad range of novel targeted agents in development are undergoing clinical studies with companion profiling to determine the best-responding patient population. Although the present focus of profiling lies in genetic analyses, additional tests of RNA, protein, and immune parameters are being developed and incorporated in clinical research, and these methods are likely to contribute significantly to future patient selection and treatment approaches. As the advances in tumor biology and human genetics have identified promising tumor targets, the ongoing clinical evaluation of novel agents will now need to show if the promise can be translated into benefit for patients.